116 related articles for article (PubMed ID: 12179998)
1. [The role of repeated biopsies in prognosis of prostate cancer].
Romics I; Lovász S; Szabó J; Szomor L; Minik K; Bartók K; Kerényi T; Szende B
Orv Hetil; 2002 Jul; 143(27):1619-23. PubMed ID: 12179998
[TBL] [Abstract][Full Text] [Related]
2. Repeated biopsies in evaluation of therapeutic effects in prostate carcinoma.
Szende B; Romics I; Minik K; Szabó J; Torda I; Lovász S; Szomor L; Tóth L; Bély M; Kerényi T; Bartók K; Végh A
Prostate; 2001 Oct; 49(2):93-100. PubMed ID: 11582587
[TBL] [Abstract][Full Text] [Related]
3. Follow-up of prostate carcinoma patients treated with total androgen blockade by repeated map-biopsy.
Szabo J; Bartok K; Keréni T; Vegh A; Romics I; Szende B
Ann Urol (Paris); 2000 Aug; 34(4):236-9. PubMed ID: 10994142
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors in prostate cancer.
Stattin P
Scand J Urol Nephrol Suppl; 1997; 185():1-46. PubMed ID: 9249905
[TBL] [Abstract][Full Text] [Related]
5. Molecular markers and their prognostic impact in patients with advanced prostate cancer undergoing intermittent androgen suppression.
Augustin H; Freibauer C; Bayer L; Lunglmayr G; Tschurlovich F; Kuber W; Pummer K
Prostate Cancer Prostatic Dis; 2006; 9(3):279-83. PubMed ID: 16702984
[TBL] [Abstract][Full Text] [Related]
6. [Correlation between re-biopsy one year after endocrine therapy and long-term prognosis in localized prostate cancer].
Kameoka H; Katayose K; Kumakawa K; Shiraiwa Y; Uchida H; Takahashi Y; Yazaki J; Yamaguchi O
Gan To Kagaku Ryoho; 2005 Jan; 32(1):57-63. PubMed ID: 15675583
[TBL] [Abstract][Full Text] [Related]
7. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
[TBL] [Abstract][Full Text] [Related]
8. [Progression of leukoplakia is associated with changes in apoptotic and mitotic index as well as in p53 and Ki-67 expression].
Kövesi G; Szende B
Magy Onkol; 2002; 46(4):333-8. PubMed ID: 12563356
[TBL] [Abstract][Full Text] [Related]
9. Apoptosis, mitosis, p53, bcl(2), Ki-67 and clinical outcome in prostate carcinoma treated by androgen ablation.
Szende B; Romics I; Torda I; Bély M; Szegedi Z; Lovász S
Urol Int; 1999; 63(2):115-9. PubMed ID: 10592500
[TBL] [Abstract][Full Text] [Related]
10. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptor, Ki67, and p53 expression in radical prostatectomy specimens predict treatment failure in Japanese population.
Inoue T; Segawa T; Shiraishi T; Yoshida T; Toda Y; Yamada T; Kinukawa N; Kinoshita H; Kamoto T; Ogawa O
Urology; 2005 Aug; 66(2):332-7. PubMed ID: 16098362
[TBL] [Abstract][Full Text] [Related]
12. BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy.
Scherr DS; Vaughan ED; Wei J; Chung M; Felsen D; Allbright R; Knudsen BS
J Urol; 1999 Jul; 162(1):12-6; discussion 16-7. PubMed ID: 10379729
[TBL] [Abstract][Full Text] [Related]
13. Prostate biopsy: who, how and when. An update.
Djavan B; Milani S; Remzi M
Can J Urol; 2005 Feb; 12 Suppl 1():44-8; discussion 99-100. PubMed ID: 15780165
[TBL] [Abstract][Full Text] [Related]
14. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
15. Cellular changes in prostate cancer cells induced by intermittent androgen suppression.
Laitinen S; Martikainen PM; Tammela TL; Visakorpi T
Eur Urol; 2007 Sep; 52(3):725-32. PubMed ID: 17141945
[TBL] [Abstract][Full Text] [Related]
16. Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors.
Westin P; Stattin P; Damber JE; Bergh A
Am J Pathol; 1995 Jun; 146(6):1368-75. PubMed ID: 7778676
[TBL] [Abstract][Full Text] [Related]
17. Cluster analysis of p53 and Ki67 expression, apoptosis, alpha-fetoprotein, and human chorionic gonadotrophin indicates a favorable prognostic subgroup within the embryonal carcinoma germ cell tumor.
Mazumdar M; Bacik J; Tickoo SK; Dobrzynski D; Donadio A; Bajorin D; Motzer R; Reuter V; Bosl GJ
J Clin Oncol; 2003 Jul; 21(14):2679-88. PubMed ID: 12860944
[TBL] [Abstract][Full Text] [Related]
18. Absence of Bcl-2 expression favors response to the short-term administration of diethylstilbestrol diphosphate in prostate Cancer.
Nagaoka A; Kubota Y; Kurosu S; Nakada T; Bilim V; Tomita Y; Motoyama T
Prostate; 2006 Dec; 66(16):1779-87. PubMed ID: 16998806
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
Soga N; Onishi T; Arima K; Sugimura Y
Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
[TBL] [Abstract][Full Text] [Related]
20. Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x.
Pollack A; Cowen D; Troncoso P; Zagars GK; von Eschenbach AC; Meistrich ML; McDonnell T
Cancer; 2003 Apr; 97(7):1630-8. PubMed ID: 12655519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]